Suzanne L Wolden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4901557/publications.pdf

Version: 2024-02-01

190 papers 8,876 citations

50 h-index 86 g-index

194 all docs

194
docs citations

194 times ranked 7629 citing authors

#	Article	IF	Citations
1	Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience. International Journal of Radiation Oncology Biology Physics, 2006, 64, 57-62.	0.8	391
2	Randomized Comparison of Low-Dose Involved-Field Radiotherapy and No Radiotherapy for Children With Hodgkin's Disease Who Achieve a Complete Response to Chemotherapy. Journal of Clinical Oncology, 2002, 20, 3765-3771.	1.6	330
3	Abnormalities of the Thyroid in Survivors of Hodgkin's Disease: Data from the Childhood Cancer Survivor Study ¹ . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3227-3232.	3.6	313
4	Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. International Journal of Radiation Oncology Biology Physics, 2001, 49, 623-632.	0.8	271
5	Breast Cancer After Chest Radiation Therapy for Childhood Cancer. Journal of Clinical Oncology, 2014, 32, 2217-2223.	1.6	230
6	Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. Journal of Neuro-Oncology, 2010, 97, 409-418.	2.9	208
7	Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031. Journal of Clinical Oncology, 2014, 32, 3651-3658.	1.6	200
8	Radiation therapy for primary intracranial germ-cell tumors. International Journal of Radiation Oncology Biology Physics, 1995, 32, 943-949.	0.8	192
9	Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing's Family of Tumors in Children and Young Adults. Journal of Clinical Oncology, 2003, 21, 3423-3430.	1.6	167
10	Long-Term Results of CCG 5942: A Randomized Comparison of Chemotherapy With and Without Radiotherapy for Children With Hodgkin's Lymphoma—A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 3174-3180.	1.6	155
11	The impact of gross total resection on local control and survival in high-risk neuroblastoma. Journal of Pediatric Surgery, 2004, 39, 412-417.	1.6	154
12	Long-term Outcomes in Survivors of Neuroblastoma: A Report From the Childhood Cancer Survivor Study. Journal of the National Cancer Institute, 2009, 101, 1131-1140.	6.3	153
13	Indications for Radiotherapy and Chemotherapy After Complete Resection in Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Studies I to III. Journal of Clinical Oncology, 1999, 17, 3468-3475.	1.6	152
14	Sensorineural hearing loss in combined modality treatment of nasopharyngeal carcinoma. Cancer, 2006, 106, 820-829.	4.1	152
15	Long-term complications in survivors of advanced stage neuroblastoma. Pediatric Blood and Cancer, 2005, 45, 324-332.	1.5	149
16	A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2006, 66, 966-974.	0.8	146
17	Management of Breast Cancer After Hodgkin's Disease. Journal of Clinical Oncology, 2000, 18, 765-765.	1.6	138
18	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2018, 36, 2770-2777.	1.6	124

#	Article	IF	Citations
19	Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya 131-I-3F8. Journal of Clinical Oncology, 2007, 25, 5465-5470.	1.6	121
20	Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and Surgery. Journal of Clinical Oncology, 2001, 19, 2821-2828.	1.6	119
21	Correlation of Osteoradionecrosis and Dental Events With Dosimetric Parameters in Intensity-Modulated Radiation Therapy for Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, e207-e213.	0.8	114
22	Intensity-Modulated Radiotherapy in Postoperative Treatment of Oral Cavity Cancers. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1096-1103.	0.8	109
23	Influence of radiation therapy parameters on outcome in children treated with radiation therapy for localized parameningeal rhabdomyosarcoma in Intergroup Rhabdomyosarcoma Study Group trials II through IV. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1027-1038.	0.8	106
24	Patterns of Failure Using a Conformal Radiation Therapy Tumor Bed Boost for Medulloblastoma. Journal of Clinical Oncology, 2003, 21, 3079-3083.	1.6	97
25	Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children's Oncology Group Soft Tissue Sarcoma Committee. Journal of Clinical Oncology, 2013, 31, 3226-3232.	1.6	96
26	Radiation therapy for Ewing's sarcoma: Results from Memorial Sloan-Kettering in the modern era. International Journal of Radiation Oncology Biology Physics, 2006, 64, 544-550.	0.8	94
27	Intensity-Modulated Radiotherapy. Cancer Journal (Sudbury, Mass), 2002, 8, 164-176.	2.0	91
28	Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. Cancer Medicine, 2019, 8, 6437-6448.	2.8	90
29	A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study. Lancet Oncology, The, 2020, 21, 145-161.	10.7	89
30	Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1432-1438.	0.8	82
31	Treatment results of 165 pediatric patients with non-metastatic nasopharyngeal carcinoma: A Rare Cancer Network study. Radiotherapy and Oncology, 2006, 81, 39-46.	0.6	80
32	Hypofractionated Dose-Painting Intensity Modulated Radiation Therapy With Chemotherapy for Nasopharyngeal Carcinoma: AAProspective Trial. International Journal of Radiation Oncology Biology Physics, 2011, 80, 148-153.	0.8	78
33	Assessment of Response to Induction Therapy and Its Influence on 5-Year Failure-Free Survival in Group III Rhabdomyosarcoma: The Intergroup Rhabdomyosarcoma Study-IV Experienceâ€"A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Journal of Clinical Oncology, 2007, 25, 4909-4913.	1.6	76
34	A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. Radiotherapy and Oncology, 2014, 111, 382-387.	0.6	75
35	Accelerated Concomitant Boost Radiotherapy and Chemotherapy for Advanced Nasopharyngeal Carcinoma. Journal of Clinical Oncology, 2001, 19, 1105-1110.	1.6	73
36	PET for Staging in Rhabdomyosarcoma: An Evaluation of PET as an Adjunct to Current Staging Tools. Journal of Pediatric Hematology/Oncology, 2007, 29, 9-14.	0.6	72

#	Article	IF	Citations
37	Local control with multimodality therapy for Stage 4 neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2000, 46, 969-974.	0.8	71
38	Local Control With Reduced-Dose Radiotherapy for Low-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group D9602 Study. International Journal of Radiation Oncology Biology Physics, 2012, 83, 720-726.	0.8	70
39	Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review. Advances in Radiation Oncology, 2019, 4, 520-531.	1.2	69
40	Adult Rhabdomyosarcoma Survival Improved With Treatment on Multimodality Protocols. International Journal of Radiation Oncology Biology Physics, 2013, 86, 58-63.	0.8	68
41	Reirradiation for recurrent medulloblastoma. Cancer, 2011, 117, 4977-4982.	4.1	65
42	Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1229-1234.	0.8	64
43	Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2009, 27, 3705-3711.	1.6	64
44	Reduced Toxicity With Intensity Modulated Radiation Therapy (IMRT) for Desmoplastic Small Round Cell Tumor (DSRCT): An Update on the Whole Abdominopelvic Radiation Therapy (WAP-RT) Experience. International Journal of Radiation Oncology Biology Physics, 2013, 85, e67-e72.	0.8	61
45	Predicting Outcome in Patients with Rhabdomyosarcoma: Role of [18F]Fluorodeoxyglucose Positron Emission Tomography. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1136-1142.	0.8	61
46	Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer. International Journal of Radiation Oncology Biology Physics, 2000, 46, 859-864.	0.8	60
47	Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro-Oncology, 2021, 23, 134-143.	1.2	56
48	Current status of radiotherapy with proton and light ion beams. Cancer, 2007, 109, 1227-1238.	4.1	55
49	Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: AÂReport From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1071-1076.	0.8	55
50	Increased local failure for patients with intermediateâ€risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. Cancer, 2019, 125, 3242-3248.	4.1	55
51	The American Brachytherapy Society consensus statement on intraoperative radiation therapy. Brachytherapy, 2019, 18, 242-257.	0.5	53
52	Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. Oral Oncology, 2015, 51, 716-723.	1.5	52
53	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncology, 2014, 50, 947-955.	1.5	51
54	Delayed primary excision with subsequent modification of radiotherapy dose for intermediateâ€risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. International Journal of Cancer, 2015, 137, 204-211.	5.1	50

#	Article	IF	CITATIONS
55	Positron Emission Tomography (PET) Evaluation After Initial Chemotherapy and Radiation Therapy Predicts Local Control in Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, 996-1002.	0.8	49
56	Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. Journal of Clinical Oncology, 2022, 40, 3858-3867.	1.6	47
57	Late Toxicities of Intensityâ€Modulated Radiation Therapy for Head and Neck Rhabdomyosarcoma. Pediatric Blood and Cancer, 2016, 63, 1608-1614.	1.5	46
58	A phase II study of radioimmunotherapy with intraventricular ¹³¹ lâ€3F8 for medulloblastoma. Pediatric Blood and Cancer, 2018, 65, e26754.	1.5	46
59	The challenging role of radiation therapy for very young children with rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1177-1184.	0.8	44
60	Risk Factors and Predictors of Severity Score and Complications of Pediatric Hemorrhagic Cystitis. Journal of Urology, 2014, 191, 186-192.	0.4	44
61	Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. Oral Oncology, 2016, 53, 67-73.	1.5	44
62	Sarcomas Across the Age Spectrum. Seminars in Radiation Oncology, 2010, 20, 45-51.	2.2	43
63	Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatric Blood and Cancer, 2017, 64, e26278.	1.5	43
64	Disease Control and Ototoxicity Using Intensity-Modulated Radiation Therapy Tumor-Bed Boost for Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2011, 81, e15-e20.	0.8	42
65	Influence of Noncompliance With Radiation Therapy Protocol Guidelines and Operative Bed Recurrences for Children With Rhabdomyosarcoma and Microscopic Residual Disease: A Report From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2011, 80, 333-338.	0.8	42
66	Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. Head and Neck, 2012, 34, 753-757.	2.0	41
67	Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. European Journal of Cancer, 2014, 50, 816-823.	2.8	40
68	Localized vaginal/uterine rhabdomyosarcomaâ€"results of a pooled analysis from four international cooperative groups. Pediatric Blood and Cancer, 2018, 65, e27096.	1.5	40
69	American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) Practice Guideline for the Performance of Total Body Irradiation (TBI). American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 97-101.	1.3	39
70	Intraoperative high-dose-rate brachytherapy for pediatric solid tumors: a 10-year experience. Brachytherapy, 2003, 2, 139-146.	0.5	36
71	Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2016, 96, 393-400.	0.8	36
72	The Effect of Radiation Timing on Patients With High-Risk Features of Parameningeal Rhabdomyosarcoma: An Analysis of IRS-IV and D9803. International Journal of Radiation Oncology Biology Physics, 2013, 87, 512-516.	0.8	35

#	Article	IF	Citations
73	106Ru plaque brachytherapy for uveal melanoma: Factors associated with local tumor recurrence. Brachytherapy, 2014, 13, 584-590.	0.5	34
74	The Children's Oncology Group Radiation Oncology Discipline: 15ÂYears of Contributions to the Treatment of Childhood Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 860-874.	0.8	34
75	Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2019, 103, 19-27.	0.8	34
76	Comparison of Treatment Results Between Adult and Juvenile Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1064-1070.	0.8	33
77	Protons for Craniospinal Radiation: Are Clinical Data Important?. International Journal of Radiation Oncology Biology Physics, 2013, 87, 231-232.	0.8	33
78	45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARSTO331 chemotherapy. Pediatric Blood and Cancer, 2017, 64, e26540.	1.5	33
79	Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma. Clinical Cancer Research, 2020, 26, 1135-1140.	7.0	33
80	A clinicopathologic study of head and neck rhabdomyosarcomas showing FOXO1 fusion-positive alveolar and MYOD1 -mutant sclerosing are associated with unfavorable outcome. Oral Oncology, 2016, 61, 89-97.	1.5	32
81	20-Year Experience With Intraoperative High-Dose-Rate Brachytherapy for Pediatric Sarcoma: Outcomes, Toxicity, and Practice Recommendations. International Journal of Radiation Oncology Biology Physics, 2014, 90, 362-368.	0.8	31
82	Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?. Radiology and Oncology, 2014, 48, 56-61.	1.7	30
83	Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma. Pediatric Blood and Cancer, 2015, 62, 445-449.	1.5	30
84	Cardiac-Sparing Whole Lung IMRT in Patients With Pediatric Tumors and Lung Metastasis: Final Report of a Prospective Multicenter Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 28-37.	0.8	30
85	Cardiovascular Risk Factors in Survivors of Childhood Hematopoietic Cell Transplantation Treated with Total Body Irradiation: A Longitudinal Analysis. Biology of Blood and Marrow Transplantation, 2017, 23, 475-482.	2.0	29
86	Local control, survival, and operative morbidity and mortality after re-resection, and intraoperative radiation therapy for recurrent or persistent primary high-risk neuroblastoma. Journal of Pediatric Surgery, 2011, 46, 97-102.	1.6	28
87	Parameningeal Rhabdomyosarcoma: Outcomes and Opportunities. International Journal of Radiation Oncology Biology Physics, 2013, 85, e61-e66.	0.8	28
88	Radiation Dose and Volume to the Pancreas and Subsequent Risk of Diabetes Mellitus: A Report from the Childhood Cancer Survivor Study. Journal of the National Cancer Institute, 2020, 112, 525-532.	6.3	28
89	Pulmonary metastasectomy in pediatric/adolescent patients with synovial sarcoma: An institutional review. Journal of Pediatric Surgery, 2013, 48, 757-763.	1.6	27
90	Whole Lung Irradiation for Adults With Pulmonary Metastases From Ewing Sarcoma. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1069-1075.	0.8	27

#	Article	IF	CITATIONS
91	Patterns of Relapse From a Phase 3 Study ofÂResponse-Based Therapy for Intermediate-Risk Hodgkin Lymphoma (AHOD0031): A Report From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 60-66.	0.8	27
92	Morbidity and mortality after treatment of Ewing sarcoma: A singleâ€institution experience. Pediatric Blood and Cancer, 2017, 64, e26562.	1.5	27
93	Central nervous system relapse of rhabdomyosarcoma. Pediatric Blood and Cancer, 2018, 65, e26710.	1.5	27
94	Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. Journal of Neuro-Oncology, 2018, 136, 95-104.	2.9	26
95	TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma. British Journal of Cancer, 2021, 125, 576-581.	6.4	26
96	Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma. Cancer, 2003, 97, 179-185.	4.1	25
97	Impact of lowâ€dose involvedâ€field radiation therapy on pediatric patients with lymphocyteâ€predominant Hodgkin lymphoma treated with chemotherapy: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2012, 59, 1284-1289.	1.5	25
98	Long-term effect of chemotherapy–intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients. Pediatric Hematology and Oncology, 2016, 33, 383-392.	0.8	25
99	Concurrent radiation with irinotecan and carboplatin in intermediate―and high―isk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study. Pediatric Blood and Cancer, 2013, 60, 242-247.	1.5	23
100	Treatment and outcome of adultâ€onset neuroblastoma. International Journal of Cancer, 2018, 143, 1249-1258.	5.1	23
101	Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Desmoplastic Small Round Cell Tumor. Sarcoma, 2015, 2015, 1-9.	1.3	21
102	Screening for thyroid cancer in survivors of childhood and young adult cancer treated with neck radiation. Journal of Cancer Survivorship, 2017, 11, 302-308.	2.9	21
103	Favorable outcomes after whole abdominopelvic radiation therapy for pediatric and young adult sarcoma. Pediatric Blood and Cancer, 2014, 61, 1565-1569.	1.5	20
104	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. Oral Oncology, 2014, 50, 863-868.	1.5	20
105	Ovarian function in survivors of childhood medulloblastoma: Impact of reduced dose craniospinal irradiation and highâ€dose chemotherapy with autologous stem cell rescue. Pediatric Blood and Cancer, 2015, 62, 317-321.	1.5	20
106	Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer. JAMA Dermatology, 2020, 156, 963.	4.1	20
107	Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984–1997: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2010, 55, 612-616.	1.5	19
108	Patterns of Failure for Rhabdomyosarcoma of the Perineal and Perianal Region. International Journal of Radiation Oncology Biology Physics, 2014, 89, 82-87.	0.8	19

#	Article	IF	Citations
109	Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial. International Journal of Radiation Oncology Biology Physics, 2016, 96, 943-950.	0.8	19
110	Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1204-1209.	0.8	19
111	Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 058-064.	0.8	19
112	Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2021, 127, 275-283.	4.1	19
113	Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Softâ€Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer, 2023, 70, e28601.	1.5	18
114	Rhabdomyosarcoma. Pediatric Blood and Cancer, 2021, 68, e28254.	1.5	18
115	Metabolic response as assessed by ¹⁸ Fâ€fluorodeoxyglucose positron emission tomographyâ€computed tomography does not predict outcome in patients with intermediateâ€or highâ€risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Cancer Medicine. 2021. 10. 857-866.	2.8	18
116	Radiotherapy in the multimodal treatment of extrarenal extracranial malignant rhabdoid tumors. Pediatric Blood and Cancer, 2008, 50, 167-169.	1.5	17
117	Advances in Radiation Therapy in Pediatric Neuro-oncology. Journal of Child Neurology, 2016, 31, 506-516.	1.4	17
118	Paratesticular rhabdomyosarcoma: Importance of initial therapy. Journal of Pediatric Surgery, 2017, 52, 304-308.	1.6	17
119	Doseâ€escalation is needed for gross disease in highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e27009.	1.5	17
120	Radiation Therapy for Non-Rhabdomyosarcoma Soft Tissue Sarcomas in Adolescents and Young Adults. Journal of Pediatric Hematology/Oncology, 2005, 27, 212-214.	0.6	16
121	Whole Neuraxis Irradiation to Address Central Nervous System Relapse in High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2010, 78, 849-854.	0.8	16
122	Second cancer risk in childhood cancer survivors treated with intensityâ€modulated radiation therapy (IMRT). Pediatric Blood and Cancer, 2015, 62, 311-316.	1.5	16
123	Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy. Head and Neck, 2016, 38, E426-31.	2.0	16
124	Patterns of relapse for children with localized intracranial ependymoma. Journal of Neuro-Oncology, 2018, 138, 435-445.	2.9	16
125	Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. Blood, 2021, 137, 1449-1456.	1.4	16
126	Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 2021, 39, 2266-2275.	1.6	16

#	Article	IF	CITATIONS
127	Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. Journal of Clinical Oncology, 2021, 39, 3927-3937.	1.6	16
128	Brainâ€sparing radiotherapy for neuroblastoma skull metastases. Pediatric Blood and Cancer, 2008, 50, 1163-1168.	1.5	15
129	Children's Oncology Group's 2013 blueprint for research: Radiation oncology. Pediatric Blood and Cancer, 2013, 60, 1037-1043.	1.5	15
130	Intensityâ€modulated radiation therapy with doseâ€painting for pediatric sarcomas with pulmonary metastases. Pediatric Blood and Cancer, 2013, 60, 1616-1620.	1.5	15
131	Intensityâ€Modulated Radiation Therapy With Dose Painting: A Brainâ€Sparing Technique for Intracranial Germ Cell Tumors. Pediatric Blood and Cancer, 2016, 63, 646-651.	1.5	15
132	Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1457-1464.	0.8	15
133	Radiotherapy Quality Assurance Report From Children's Oncology Group AHOD0031. International Journal of Radiation Oncology Biology Physics, 2015, 91, 1065-1071.	0.8	14
134	Insulin and glucose homeostasis in childhood cancer survivors treated with abdominal radiation: A pilot study. Pediatric Blood and Cancer, 2018, 65, e27304.	1.5	14
135	Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1151-1157.	0.8	14
136	Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. International Journal of Cancer, 2020, 147, 1419-1426.	5.1	14
137	AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group. Blood, 2010, 116, 766-766.	1.4	14
138	Ewing sarcoma in adults treated with modern radiotherapy techniques. Radiotherapy and Oncology, 2014, 113, 248-253.	0.6	13
139	Shortâ€Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis. Pediatric Blood and Cancer, 2016, 63, 731-733.	1.5	13
140	Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 486-493.	0.8	13
141	Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective Trial. International Journal of Radiation Oncology Biology Physics, 2019, 104, 409-414.	0.8	13
142	Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups. Pediatric Blood and Cancer, 2021, 68, e28832.	1.5	13
143	Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediateâ€risk Hodgkin lymphoma treated with chemoâ€radiation therapy: FDGâ€PET parameter analysis in a subgroup from COG AHOD0031. Pediatric Blood and Cancer, 2021, 68, e29212.	1.5	13
144	Genome-Wide Screening for Radiation Response Factors in Head and Neck Cancer. Laryngoscope, 2000, 110, 1251-1256.	2.0	11

#	Article	IF	CITATIONS
145	Practice patterns and recommendations for pediatric imageâ€guided radiotherapy: A Children's Oncology Group report. Pediatric Blood and Cancer, 2020, 67, e28629.	1.5	11
146	Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. International Journal of Cancer, 2020, 147, 3168-3176.	5.1	11
147	Intensity Modulated Radiation Therapy With Dose Painting to Treat Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2012, 84, e371-e377.	0.8	10
148	<i>MYCN</i> -amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy. Oncotarget, 2017, 8, 95293-95302.	1.8	10
149	Hyperfractionated Low-Dose (21 Gy) Radiotherapy for Cranial Skeletal Metastases in Patients With High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1181-1186.	0.8	9
150	Quality of Radiotherapy Reporting in Randomized Controlled Trials of Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: In Regard to Bekelman and Yahalom (Int J Radiat Oncol Biol Phys) Tj ETQq0 0 0 rgB ⁻	Г/O væs lock	109Tf 50 537
151	Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2017, 39, 547-554.	0.6	9
152	Radiotherapy and Late Effects. Pediatric Clinics of North America, 2020, 67, 1051-1067.	1.8	9
153	Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts. Journal of Clinical Oncology, 2021, 39, 3012-3021.	1.6	9
154	Reduced-volume radiotherapy for patients with localized intracranial nongerminoma germ cell tumors. Journal of Neuro-Oncology, 2017, 134, 349-356.	2.9	8
155	Early Axial Growth Outcomes of Pediatric Patients Receiving Proton Craniospinal Irradiation. Journal of Pediatric Hematology/Oncology, 2018, 40, 574-579.	0.6	8
156	The potential role of MR-guided adaptive radiotherapy in pediatric oncology: Results from a SIOPE-COG survey. Clinical and Translational Radiation Oncology, 2021, 29, 71-78.	1.7	8
157	Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis. Neuro-Oncology Advances, 2021, 3, vdab181.	0.7	8
158	Local control of parameningeal rhabdomyosarcoma: An expert consensus guideline from the International Soft Tissue Sarcoma Consortium (INSTRuCT). Pediatric Blood and Cancer, 2022, 69, e29751.	1.5	8
159	Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers. Head and Neck, 2015, 37, 1633-1641.	2.0	7
160	Reducedâ€dose craniospinal irradiation for central nervous system relapsed neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28364.	1.5	7
161	Second cancer risk in childhood cancer survivors treated with intensityâ€modulated radiation therapy: An updated analysis of more than 10Âyears of followâ€up. Pediatric Blood and Cancer, 2022, 69, e29600.	1.5	7
162	Intraoral angiosarcoma: Treatment with a brachytherapy prosthesis. Journal of Prosthetic Dentistry, 2015, 113, 242-245.	2.8	6

#	Article	IF	CITATIONS
163	Patterns of Involved-Field Radiation Therapy Protocol Deviations in Pediatric Versus Adolescent and Young Adults With Hodgkin Lymphoma: A Report From the Children's Oncology Group AHOD0031. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1119-1125.	0.8	6
164	Novel intraoperative radiotherapy utilizing prefabricated custom three-dimensionally printed high-dose-rate applicators. Brachytherapy, 2019, 18, 277-284.	0.5	6
165	Do children and adolescents with completely resected alveolar rhabdomyosarcoma require adjuvant radiation? A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2020, 67, e28243.	1.5	6
166	Collision in the inferior olive: hypertrophic olivary degeneration complicated by radiation necrosis in brainstem primitive neuroendocrine tumor. Clinical Imaging, 2012, 36, 371-374.	1.5	5
167	Assessment of pulmonary outcomes, exercise capacity, and longitudinal changes in lung function in pediatric survivors of highâ€risk neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27960.	1.5	5
168	An evaluation of machine learning techniques to predict the outcome of children treated for Hodgkin-Lymphoma on the AHOD0031 trial. Applied Artificial Intelligence, 2020, 34, 1100-1114.	3.2	5
169	High-dose-rate brachytherapy of rhabdomyosarcoma limited to the external auditory canal. Brachytherapy, 2017, 16, 181-185.	0.5	4
170	Fabrication of a custom brachytherapy appliance. Journal of Prosthetic Dentistry, 2019, 121, 535-537.	2.8	4
171	Mandibular metastases in neuroblastoma: Outcomes and dental sequelae. Pediatric Blood and Cancer, 2021, 68, e28918.	1.5	4
172	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. Journal of Radiation Oncology, 2013, 2, 285-291.	0.7	3
173	Patterns of failure after salvage re-irradiation for recurrent head and neck cancer: implications for field design and consolidation therapy. Journal of Radiation Oncology, 2014, 3, 139-145.	0.7	3
174	Highâ€doseâ€rate brachytherapy for vaginal rhabdomyosarcoma using a personalized mold in a 20â€month old patient. Pediatric Blood and Cancer, 2015, 62, 531-532.	1.5	3
175	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522.	27.6	3
176	SYMPTOMATIC CHIARI TYPE I MALFORMATION AFTER RADIATION THERAPY IN AN INFANT. Neurosurgery, 2007, 60, E782-E782.	1.1	2
177	Customized high-dose-rate brachytherapy using MRI planning for vaginal rhabdomyosarcoma. Brachytherapy, 2015, 14, 46-50.	0.5	2
178	Thyroid neoplasms: incidental findings on extent of disease evaluation CT for other pediatric malignancies. Journal of Pediatric Surgery, 2017, 52, 938-943.	1.6	2
179	Training and education of pediatric radiation oncologists: A survey from the 2019 Pediatric Radiation Oncology Society meeting. Pediatric Blood and Cancer, 2020, 67, e28619.	1.5	2
180	Pediatric Rhabdomyosarcoma: Biology and Results of the North American Intergroup Rhabdomyosarcoma Trials., 2006,, 103-132.		1

#	Article	IF	CITATIONS
181	Neck spasms: A late sequela of head and neck irradiation. Oral Oncology, 2016, 57, e4-e5.	1.5	1
182	Automated Breast Density Measurements From Chest Computed Tomography Scans. Journal of Medical Systems, 2019, 43, 242.	3.6	1
183	Insurer's Black Box: Inexplicable Barriers to Proton Therapy Access for Young Adults. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1538-1539.	0.8	1
184	Vital organ sparing with proton therapy for pediatric Hodgkin lymphoma: Toxicity and outcomes in 50 patients. Radiotherapy and Oncology, 2022, 168, 46-52.	0.6	1
185	A New Intensified Therapeutic Regimen for Advanced Head and Neck Squamous Cell Carcinomas: Where Does It Fit Among Available Treatment Options?. Cancer Investigation, 2001, 19, 217-218.	1.3	0
186	Wholeâ€lung irradiation in the treatment of metastatic synovial sarcoma. Pediatric Blood and Cancer, 2014, 61, 2092-2093.	1.5	0
187	Radiosurgery, reirradiation, and brachytherapy. Pediatric Blood and Cancer, 2021, 68, e28531.	1.5	0
188	Pediatric Malignancies., 2011,, 481-500.		0
189	T- Cell Depleted Peripheral Blood Stem Cell (TCD-PBSC) Transplants Secure Consistent Engraftment with Low Risk of Acute or Chronic Gvhd and Favorable Disease Free Survival (DFS) and Overall Survival (OS) for Pediatric Patients (<21 years) with AML in CR1 or CR2 or MDS Including tMDS/AML. Blood. 2015. 126. 5513-5513.	1.4	0
190	Subsequent Malignant Neoplasms Among Children and Adolescents with Hodgkin Lymphoma Treated with Response-Adapted Therapy: A Report from the Children's Oncology Group Study AHOD0031. Blood, 2016, 128, 924-924.	1.4	0